Compare Merck & Co., Inc. (MRK) vs Invesco Preferred ETF (PGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Invesco Preferred ETF — how do they compare? Merck & Co., Inc. trades at $146.21 (market cap $351.28B), while Invesco Preferred ETF trades at $10.03 (market cap $3.60B). The key difference: Merck & Co., Inc. is far larger — about 97.6× Invesco Preferred ETF's market cap, and Merck & Co., Inc. pays a 2.39% dividend while Invesco Preferred ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Invesco Preferred ETF for 95 Days on average.
| MRK | PGX | |
|---|---|---|
Market Cap | $351.28B | $3.60B |
Volume | 7,969,665 | 5,986,026 |
Sector | Health | — |
52-Week High | $156.43 | $11.61 |
52-Week Low | $82.49 | $9.97 |
Typical Hold Time | 98 Days | 95 Days |
Enterprise Value | $398.04B | — |
Dividend Yield | 2.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $144.96, up 1.52% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 72.97% gross margin and 28.07% net income margin for 2025, though its P/E ratio of 113.9 indicates high valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid competitive pressures.
The outlook is mixed: analyst consensus is bullish with a $158.78 price target, but technical indicators and a high P/E suggest near-term caution. Key risks include integration challenges from acquisitions and macroeconomic headwinds affecting pharmaceutical R&D investment. Revenue growth and pipeline execution remain critical for sustained upside.
PGX trades at $10.01, up 0.4% with bearish technical indicators showing 18 sell signals versus 3 buy signals. The stock faces resistance at $10 with RSI at neutral levels. Recent dividends of $0.06 were declared for July and September 2026, providing income potential amid technical weakness.
The outlook remains cautious with strong bearish momentum in moving averages. Investment opportunity lies in dividend yield while risks include technical breakdown below $10 support. Fundamental analysis is limited without current financial ratios, requiring updated SEC filings for proper valuation assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Invesco Preferred ETF
The fund generally will invest at least 80% of its total assets in the components of the index. Strictly in accordance with its guidelines and mandated procedures, ICE Data Indices, LLC selects securities for the index, which is a market capitalization-weighted index designed to measure the performance of the fixed rate US dollar-denominated preferred securities market.
Read more on PGX →
